Publications by authors named "M Alan Menter"

Claim this Profile
T
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
A P Fernandez, E Dauden, S Gerdes, M G Lebwohl, M A Menter

J Eur Acad Dermatol Venereol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Diamant Thaçi, Bruce Strober, Kenneth B Gordon, Peter Foley, Melinda Gooderham, M Alan Menter

Dermatol Ther (Heidelb)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
M Lebwohl, A Deodhar, C E M Griffiths, M A Menter, D Poddubnyy

Br J Dermatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, Alice B Gottlieb, Alan M Mendelsohn, M Alan Menter

J Am Acad Dermatol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2).
M Alan Menter, Nehal N Mehta, Mark G Lebwohl, Alice B Gottlieb, Alan M Mendelsohn

J Drugs Dermatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis